UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000034131
Receipt No. R000038888
Scientific Title A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients
Date of disclosure of the study information 2018/10/01
Last modified on 2019/09/18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients
Acronym A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients (CMA-Ate004)
Scientific Title A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients
Scientific Title:Acronym A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients (CMA-Ate004)
Region
Japan

Condition
Condition renal cell carcinoma
Classification by specialty
Urology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To compare OS in Japanese RCC patients by PD-L1 expression status(IC0 vs IC1/2/3). OS is defined as the time from the initiation date of first line treatment to death due to any cause.
PD-L1 expression status is scored by proportion of tumor area covered with any discernible PD-L1 immune cell staining of any intensity.
Basic objectives2 Others
Basic objectives -Others Secondary objectives
1.To compare OS by PD-L1 expression status (IC0, IC1, IC2, IC3)
2.To compare OS after nephrectomy includes receiving cytoreductive nephrectomy by PD-L1 expression status.
3.To compare time to relapse after nephrectomy by PD-L1 status
4.To Compare treatment duration of first and second line therapy for recurrent or metastatic RCC by PD-L1 status
Exploratory objectives
To assess immunological exploratory biomarkers and their association with OS and clinical characteristics of RCC.
Trial characteristics_1 Others
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes OS in PD-L1 negative (IC0) and positive (IC1/2/3) patients.
OS is defined as the time from the initiation date of first line treatment to death due to any cause.
Key secondary outcomes 1.OS in each level of PD-L1 expression(IC0, IC1,IC2,IC3), OS is defined as the time from the initiation date of first line treatment to death due to any cause.
2.OS defined as the time from initial nephrectomy includes receiving cytoreductive nephrectomy to death due to any cause in PD-L1negative and positive patients.
3.Time to relapse after radical nephrectomy
4.Treatment duration of first line and second line.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Written informed consent for this study. In the case obtaining written informed consent is difficult due to death, change of address, and so on, the opt-out consent is accepted by giving patients or their relatives notification regarding the usage of their clinical information and surgical samples for the research.
2.Age at nephrectomy>=20 years
3.Patients with recurrent or metastatic RCC who have initiated first line treatment between 1 January 2010 and 31 December 2015, with representative FFPE of nephrectomy surgical specimen which are suitable for assessment of PD-L1 expression
Key exclusion criteria 1.Malignancies other than RCC is co-existed during the time from nephrectomy and death.
2.Treatment with anti-CTLA-4 antibody, anti-PD-1/PD-L1 antibodies as first-line therapy for recurrent or metastatic RCC.
Target sample size 600

Research contact person
Name of lead principal investigator
1st name Kaori
Middle name
Last name Ouch
Organization Chugai Pharmaceutical Co., Ltd.
Division name Medical Science Department
Zip code 103-8324
Address 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo 103-8324, JAPAN
TEL 03-3273-0866
Email cma-clinicaltrial@chugai-pharm.co.jp

Public contact
Name of contact person
1st name Tomoko
Middle name
Last name Kotani
Organization SRL Medisearch Inc.
Division name Clinical Research Development 3
Zip code 163-1310
Address Shinjuku I-Land Tower 10F 6-5-1, Nishishinjuku, Shinjuku-ku, Tokyo 163-1310, JAPAN
TEL 03-6692-0499
Homepage URL
Email tomoko.kotani@miraca.com

Sponsor
Institute Chugai Pharmaceutical Co., Ltd.
Institute
Department

Funding Source
Organization Chugai Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Non-Profit Organization MINS Institutional Review Board
Address 5-20-9-401, Mita, Minato-ku, Tokyo
Tel 03-6416-1868
Email npo-mins@j-irb.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 北海道大学病院(北海道)、札幌医科大学附属病院(北海道)、弘前大学医学部附属病院(青森県)、岩手医科大学附属病院(岩手県)、筑波大学附属病院(茨城県)、東邦大学医療センター佐倉病院(千葉県)、慶應義塾大学病院(東京都)、東京医科歯科大学医学部附属病院(東京都)日本医科大学付属病院(東京都)、北里大学病院(神奈川県)、横浜市立大学附属病院(神奈川県)、新潟大学医歯学総合病院(新潟県)、富山大学附属病院(富山県)、静岡県立静岡がんセンター(静岡県)、浜松医科大学医学部附属病院(静岡県)、愛知医科大学病院(愛知県)、名古屋大学医学部附属病院(愛知県)、京都大学医学部附属病院(京都府)、大阪市立大学医学部附属病院(大阪府)、大阪大学医学部附属病院(大阪府)、近畿大学医学部附属病院(大阪府)、神戸大学医学部附属病院(兵庫県)、奈良県立医科大学附属病院(奈良県)、岡山大学病院(岡山県)、徳島大学病院(徳島県)、香川大学医学部附属病院(香川県)、九州大学病院(福岡県)、長崎大学病院(長崎県)、熊本大学医学部附属病院(熊本県)

Other administrative information
Date of disclosure of the study information
2018 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 830
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2018 Year 08 Month 09 Day
Date of IRB
2018 Year 07 Month 19 Day
Anticipated trial start date
2019 Year 01 Month 21 Day
Last follow-up date
2019 Year 07 Month 18 Day
Date of closure to data entry
2019 Year 07 Month 18 Day
Date trial data considered complete
2019 Year 09 Month 02 Day
Date analysis concluded
2019 Year 09 Month 27 Day

Other
Other related information Retrospective study for Japanese Renal cell carcinoma patients.
Archived specimens from each hospitals are obtained, then assess PD-L1 status by central laboratory.

Management information
Registered date
2018 Year 09 Month 14 Day
Last modified on
2019 Year 09 Month 18 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038888

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.